You can buy or sell Cabaletta Bio and other stocks, options, and ETFs commission-free!
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA. The listed name for CABA is Cabaletta Bio, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 29, Pre-Market